The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
about
Tiotropium versus placebo for chronic obstructive pulmonary diseaseLong-acting beta2-agonists for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: an overview and network meta-analysisLong-acting beta2-agonists for chronic obstructive pulmonary diseaseTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseTiotropium versus placebo for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseThe effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseLong-acting beta 2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta 2 -agonist alone for chronic obstructive pulmonary diseaseTiotropium versus placebo for chronic obstructive pulmonary diseaseCombination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary diseaseThe added effect of inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary diseaseCombination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary diseaseSpecific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary diseaseUmeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a reviewA novel model-based approach for dose determination of glycopyrronium bromide in COPDA dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.The role of bronchodilator treatment in the prevention of exacerbations of COPD.Indacaterol in chronic obstructive pulmonary disease: an update for clinicians.Indacaterol: a comprehensive review.Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.An update on bronchodilators in Phase I and II clinical trials.Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a reviewMuscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease.Oxidation pathway and exacerbations in COPD: the role of NAC.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis.How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients.Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β2-adrenoceptor agonistsDual bronchodilation and exacerbations of COPD.The Challenges of Precision Medicine in COPD.Indacaterol for the treatment of chronic obstructive pulmonary disease.
P2860
Q24194833-92DD14F9-4B94-44D2-9325-4F3E8AD7BEA6Q24197467-D564AB8A-D35E-4E56-886C-53A8D2EC8FE4Q24197853-03426231-4BA1-440F-81D6-056E44C51280Q24197946-79174F84-A73F-4411-BC90-989F8BD8F55DQ24198970-B416B4EB-B9EF-41F2-A050-E6961DEC37B9Q24200476-BCAE7A77-6001-4CFB-A011-BC3F789D1DC1Q24202175-AB5056DA-43E0-40EF-805A-CF62627B30B2Q24202279-6BF0AB7F-9020-4DA1-A531-D223273F795AQ24234294-23804840-8CC9-4F88-9F1D-23907BEB56EEQ24234343-3B511681-DB25-419D-B73B-C699176CD46FQ24234544-DEB97B2C-5826-4FBD-84F8-8A53686F2B54Q24235153-978146E2-CA14-4FC4-A818-5211C5049387Q24235761-568683A4-E5FF-4FE6-8205-1A4A8B451D5EQ24236471-637F0692-16A3-4BA7-B1E7-B0A52E13965CQ26471530-CD91FABC-1CB4-4349-84B4-4D168D2692A6Q26770504-ACE2CFFB-42A2-40B4-AC22-F762635688D1Q27015685-549EF954-8F98-4950-BA09-399BEAC71696Q34502782-24CCDBA8-B437-4423-B0C3-0AB547A41A82Q35060604-030CDD2D-A458-479C-A54B-93D40DA8EDECQ36438669-52378148-9EF4-479F-A124-602FA38087D8Q36443777-54810272-1D6D-490D-8A8E-7CD00C2F6B82Q37057061-C45802B0-37FA-4F3D-95BD-CEF813D541DFQ37846698-6F9230BE-F447-4659-9989-8610ACA44052Q37867838-711F84A4-97A9-43FE-BB11-C979D9E9109FQ38037123-B6D0226C-C1F5-4D73-ADD4-3647057B91FCQ38057220-8534969B-98F9-4979-AC3C-7B155DBBE742Q38072277-B7F0B9B5-4512-4011-B5F1-3AE2EFA3467FQ38148145-4CB4AEEB-CA51-4171-BDB6-3CFFF447B605Q38199533-12E6242A-2FDB-4BBD-9F91-E725759F626AQ38248438-2EFAD552-CB9F-4EB6-95E8-DF0982F2AF5EQ38371305-5F2CABDA-6BFB-483A-8BC9-412C4E0DC68EQ38633304-7E1990EF-6011-4D14-8C6C-9975A96259C2Q38740756-DE6527F3-F7FE-4034-ABFA-A82340BE025FQ38906820-519EC279-ABF6-4F50-A4E5-E41A7722CEE4Q39030602-CA642110-C1F8-4411-A60C-0D26AAFEA977Q41908094-8EE34BD2-0E2B-4757-B135-4CBD603CCA0AQ42283741-7B2A38D4-9EC5-4F8E-A61B-415AA02ED8FDQ42384700-E0F38500-A0B6-4050-84B4-5134A2638A13Q47962475-B17CC2AD-B756-4D68-BC69-676F48575920Q48059168-25C436AF-3DB3-49C1-8D77-0C4748F68ABA
P2860
The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The short, the long and the "u ...... obstructive pulmonary disease.
@en
The short, the long and the "u ...... obstructive pulmonary disease.
@nl
type
label
The short, the long and the "u ...... obstructive pulmonary disease.
@en
The short, the long and the "u ...... obstructive pulmonary disease.
@nl
prefLabel
The short, the long and the "u ...... obstructive pulmonary disease.
@en
The short, the long and the "u ...... obstructive pulmonary disease.
@nl
P2860
P1433
P1476
The short, the long and the "u ...... obstructive pulmonary disease.
@en
P2093
Jutta Beier
Kai M Beeh
P2860
P2888
P304
P356
10.1007/S12325-010-0017-6
P407
P577
2010-03-01T00:00:00Z